226 related articles for article (PubMed ID: 29530719)
21. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
22. RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice.
Kittaka M; Yoshimoto T; Hoffman H; Levitan ME; Ueki Y
Bone Rep; 2020 Jun; 12():100258. PubMed ID: 32258251
[TBL] [Abstract][Full Text] [Related]
23. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
[TBL] [Abstract][Full Text] [Related]
24. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of mouse bone marrow stromal cell lines immortalized by temperature-sensitive SV40 T antigen: supportive activity for osteoclast differentiation.
Takeshita S; Arai S; Kudo A
Bone; 2001 Sep; 29(3):236-41. PubMed ID: 11557367
[TBL] [Abstract][Full Text] [Related]
26. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
[TBL] [Abstract][Full Text] [Related]
27. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
28. The androgen receptor has no direct antiresorptive actions in mouse osteoclasts.
Sinnesael M; Jardi F; Deboel L; Laurent MR; Dubois V; Zajac JD; Davey RA; Carmeliet G; Claessens F; Vanderschueren D
Mol Cell Endocrinol; 2015 Aug; 411():198-206. PubMed ID: 25958043
[TBL] [Abstract][Full Text] [Related]
29. Palmatine attenuates osteoclast differentiation and function through inhibition of receptor activator of nuclear factor-κb ligand expression in osteoblast cells.
Lee JW; Mase N; Yonezawa T; Seo HJ; Jeon WB; Cha BY; Nagai K; Woo JT
Biol Pharm Bull; 2010; 33(10):1733-9. PubMed ID: 20930384
[TBL] [Abstract][Full Text] [Related]
30. Jawing about TNF: new hope for cherubism.
Novack DV; Faccio R
Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
[TBL] [Abstract][Full Text] [Related]
31. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
32. Comparison of morphological effects of PGE2 and TGFbeta on osteoclastogenesis induced by RANKL in mouse bone marrow cell cultures.
Gardner CR
Cell Tissue Res; 2007 Oct; 330(1):111-21. PubMed ID: 17694327
[TBL] [Abstract][Full Text] [Related]
33. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
Karst M; Gorny G; Galvin RJ; Oursler MJ
J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
[TBL] [Abstract][Full Text] [Related]
34. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
35. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
[TBL] [Abstract][Full Text] [Related]
36. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
38. Coculture of osteoclast precursors with rheumatoid synovial fibroblasts induces osteoclastogenesis via transforming growth factor beta-mediated down-regulation of osteoprotegerin.
Hase H; Kanno Y; Kojima H; Sakurai D; Kobata T
Arthritis Rheum; 2008 Nov; 58(11):3356-65. PubMed ID: 18975335
[TBL] [Abstract][Full Text] [Related]
39. PTH differentially regulates expression of RANKL and OPG.
Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
[TBL] [Abstract][Full Text] [Related]
40. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
